| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 20554006
[patent_doc_number] => 20260053786
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-02-26
[patent_title] => FORMULATIONS OF RADIPRODIL
[patent_app_type] => utility
[patent_app_number] => 19/376486
[patent_app_country] => US
[patent_app_date] => 2025-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4581
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19376486
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/376486 | FORMULATIONS OF RADIPRODIL | Oct 30, 2025 | Pending |
Array
(
[id] => 20458210
[patent_doc_number] => 20260007630
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-01-08
[patent_title] => COMPOSITIONS COMPRISING SELECTIVE ANDROGEN RECEPTOR MODULATOR COMPOUNDS IN COMBINATION WITH WEIGHT LOSS DRUGS AND USES THEREOF FOR QUALITY WEIGHT LOSS
[patent_app_type] => utility
[patent_app_number] => 19/319108
[patent_app_country] => US
[patent_app_date] => 2025-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43213
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19319108
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/319108 | COMPOSITIONS COMPRISING SELECTIVE ANDROGEN RECEPTOR MODULATOR COMPOUNDS IN COMBINATION WITH WEIGHT LOSS DRUGS AND USES THEREOF FOR QUALITY WEIGHT LOSS | Sep 3, 2025 | Pending |
Array
(
[id] => 20598946
[patent_doc_number] => 20260076949
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-03-19
[patent_title] => STABLE MONOHYDRATE OF DF2755A AND PROCESS FOR ITS PREPARATION
[patent_app_type] => utility
[patent_app_number] => 19/288001
[patent_app_country] => US
[patent_app_date] => 2025-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3484
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19288001
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/288001 | STABLE MONOHYDRATE OF DF2755A AND PROCESS FOR ITS PREPARATION | Jul 31, 2025 | Pending |
Array
(
[id] => 20246776
[patent_doc_number] => 20250295645
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-25
[patent_title] => BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS-CLOVES SYNDROME)
[patent_app_type] => utility
[patent_app_number] => 19/227991
[patent_app_country] => US
[patent_app_date] => 2025-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1044
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19227991
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/227991 | BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS-CLOVES SYNDROME) | Jun 3, 2025 | Pending |
Array
(
[id] => 20206251
[patent_doc_number] => 20250275971
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-04
[patent_title] => CDK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 19/210611
[patent_app_country] => US
[patent_app_date] => 2025-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8790
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19210611
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/210611 | CDK INHIBITORS | May 15, 2025 | Pending |
Array
(
[id] => 20307915
[patent_doc_number] => 20250325544
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-23
[patent_title] => CDK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 19/210825
[patent_app_country] => US
[patent_app_date] => 2025-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8793
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19210825
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/210825 | CDK INHIBITORS | May 15, 2025 | Pending |
Array
(
[id] => 20206252
[patent_doc_number] => 20250275972
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-04
[patent_title] => CDK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 19/210983
[patent_app_country] => US
[patent_app_date] => 2025-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8830
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19210983
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/210983 | CDK INHIBITORS | May 15, 2025 | Pending |
Array
(
[id] => 20335271
[patent_doc_number] => 20250339391
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-06
[patent_title] => METHODS FOR EFFECTIVE MANAGEMENT OF PAIN
[patent_app_type] => utility
[patent_app_number] => 19/181999
[patent_app_country] => US
[patent_app_date] => 2025-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25907
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19181999
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/181999 | METHODS FOR EFFECTIVE MANAGEMENT OF PAIN | Apr 16, 2025 | Pending |
Array
(
[id] => 20134854
[patent_doc_number] => 20250241898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-31
[patent_title] => Topical Benzimidazole Formulations and Methods for Use in Treating Inflammatory Dermatoses
[patent_app_type] => utility
[patent_app_number] => 19/180752
[patent_app_country] => US
[patent_app_date] => 2025-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14534
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19180752
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/180752 | Topical Benzimidazole Formulations and Methods for Use in Treating Inflammatory Dermatoses | Apr 15, 2025 | Pending |
Array
(
[id] => 19846732
[patent_doc_number] => 20250092083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-20
[patent_title] => STEROL BASED IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/907013
[patent_app_country] => US
[patent_app_date] => 2024-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30665
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18907013
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/907013 | STEROL BASED IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME | Oct 3, 2024 | Pending |
Array
(
[id] => 19745552
[patent_doc_number] => 20250034117
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => Deuterated 1,3 Dihydro -2H-indole-2-one derivatives
[patent_app_type] => utility
[patent_app_number] => 18/771709
[patent_app_country] => US
[patent_app_date] => 2024-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12485
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18771709
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/771709 | Deuterated 1,3 Dihydro -2H-indole-2-one derivatives | Jul 11, 2024 | Pending |
Array
(
[id] => 19556401
[patent_doc_number] => 20240368193
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => KRAS INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/621388
[patent_app_country] => US
[patent_app_date] => 2024-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55725
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -47
[patent_words_short_claim] => 613
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621388
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/621388 | KRAS INHIBITORS | Mar 28, 2024 | Pending |
Array
(
[id] => 19667482
[patent_doc_number] => 12180209
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-12-31
[patent_title] => Pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/586021
[patent_app_country] => US
[patent_app_date] => 2024-02-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9777
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18586021
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/586021 | Pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | Feb 22, 2024 | Issued |
Array
(
[id] => 19651235
[patent_doc_number] => 12173003
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-12-24
[patent_title] => Pyrrolo[3,2-C][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/586070
[patent_app_country] => US
[patent_app_date] => 2024-02-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9777
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 352
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18586070
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/586070 | Pyrrolo[3,2-C][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | Feb 22, 2024 | Issued |
Array
(
[id] => 19389315
[patent_doc_number] => 20240279185
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/433196
[patent_app_country] => US
[patent_app_date] => 2024-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20752
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 222
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18433196
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/433196 | Aryl hydrocarbon receptor agonists and uses thereof | Feb 4, 2024 | Issued |
Array
(
[id] => 19311528
[patent_doc_number] => 12037331
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-07-16
[patent_title] => 1-Cyclopropyl-6-fluoro-7-4((5-(4-methoxybenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2h)-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory and anticancer compound
[patent_app_type] => utility
[patent_app_number] => 18/430134
[patent_app_country] => US
[patent_app_date] => 2024-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 4271
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18430134
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/430134 | 1-Cyclopropyl-6-fluoro-7-4((5-(4-methoxybenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2h)-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory and anticancer compound | Jan 31, 2024 | Issued |
Array
(
[id] => 19624071
[patent_doc_number] => 12162875
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-12-10
[patent_title] => 1-cyclopropyl-6-fluoro-7-(4-((5(4-methoxybenzylideneamino-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory and anticancer compound
[patent_app_type] => utility
[patent_app_number] => 18/430131
[patent_app_country] => US
[patent_app_date] => 2024-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4238
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18430131
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/430131 | 1-cyclopropyl-6-fluoro-7-(4-((5(4-methoxybenzylideneamino-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory and anticancer compound | Jan 31, 2024 | Issued |
Array
(
[id] => 19331280
[patent_doc_number] => 20240245710
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => Combination Therapy For Prostate Cancer
[patent_app_type] => utility
[patent_app_number] => 18/429778
[patent_app_country] => US
[patent_app_date] => 2024-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9551
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18429778
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/429778 | Combination Therapy For Prostate Cancer | Jan 31, 2024 | Pending |
| 18/430138 | 1-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | Jan 31, 2024 | Abandoned |
Array
(
[id] => 19343455
[patent_doc_number] => 20240252418
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => Additives (Adjuvants, Anti Freezing Agents, Antimicrobial and Antioxidants) in Natural Deep Eutectic Solvents and Mixtures
[patent_app_type] => utility
[patent_app_number] => 18/427860
[patent_app_country] => US
[patent_app_date] => 2024-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7176
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427860
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/427860 | Additives (Adjuvants, Anti Freezing Agents, Antimicrobial and Antioxidants) in Natural Deep Eutectic Solvents and Mixtures | Jan 30, 2024 | Pending |